AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02456558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous deferiprone
Description: In Cohort 1, the subjects who were randomized to get active product will receive deferiprone at a dose of 1.5 g per infusion, and if there are no significant safety concerns, the subjects in Cohort 2 who were randomized to get active product will receive it a a dose of 2 g per infusion.
Study NCT02456558 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In both cohorts, the subjects who were randomized to get placebo will receive an infusion of placebo solution that is equal in volume to that of the active product.
Study NCT00627146 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ChAgly CD3
Description: 6 days treatment 8mg/d intravenous
Study NCT00627146 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 6 days
Study NCT01908400 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Intravenous transfer of BMMNC
Description: Intervention therapy , Total 3 doses ,in 30 days ,in 7days interval Intravenous transfer of Autologous Bone Marrow derived Mono Nuclear Stem Cell (BMMNCs)
Study NCT00480987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 30 mg/m\^2 IV days 1-4
Study NCT00480987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m\^2 IV days 2-6
Study NCT00480987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 500 mg/m\^2 by IV continuous infusion days 2-6
Study NCT01432951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzastaurin
Description: Administered orally
Study NCT01145638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iron isomaltoside 1000
Description: intravenously as bolus or infusion, 500 mg or 1000mg up to full replacement dose
Study NCT01145638 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: iron sulphate
Description: oral, 200 mg per day (100 mg bid),12 weeks
Study NCT02519855 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ZOSTAVAX™
Description: A single blinded administration of 0.65 mL subcutaneous injection on Day 1 (concomitant) or at Week 4 (nonconcomitant)
Study NCT02519855 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo to ZOSTAVAX™
Description: A single blinded administration of 0.65 mL subcutaneous injection on Day 1 (nonconcomitant) or at Week 4 (concomitant)
Study NCT02519855 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Vaccine
Description: A single open-label administration of 0.5 mL intramuscular injection on Day 1
Study NCT01840644 — intervention group
Intervention type: OTHER
Intervention: Walking on treadmill, different velocities and incline
Description: Walking on treadmill twice, with one week interval in each session the child will walk in different velocities and incline
Study NCT02907892 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Glove change
Description: Intra-operative changing of sterile surgical gloves immediately prior to abdominal closure during cesarean section
Study NCT02910128 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: chiquichefs
Description: A project based learning using healthy trough cooking as the core of the curriculum, so children learn the academic content through cooking workshop of mediterranean diet in their school.
Study NCT00507728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: Starting dose 150 mg by mouth daily (150 mg every morning for three days; 150 mg twice a day thereafter)
Study NCT00507728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Starting dose 0.5 mg by mouth daily (0.5 mg every morning for days 1 - 3, then 0.5 mg twice a day for days 4 - 7, then 1 mg twice a day thereafter)
Study NCT00507728 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo by mouth for 12 weeks.
Study NCT00507728 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking Cessation Counseling
Description: Counseling over 8 months and telephone support calls.
Study NCT00507728 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Smoking Cessation Counseling
Description: Counseling over 8 months and telephone support calls.
Study NCT04746326 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Conservative treatment
Description: Conservative treatment was performed in patients who had no generalized peritonitis and perforation.
Study NCT03685448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: The 20 mg cabozantinib drug product is a film-coated, white, round, immediate-release tablet. Cabozantinib should not be stored above 25°C (77°F).
Study NCT04531462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: Empagliflozin
Study NCT04531462 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02673047 — intervention group
Intervention type: BIOLOGICAL
Intervention: botulinum toxin Type A
Description: Botulinum toxin Type A (Botox®) injection as prescribed as standard of care in clinical practice.
Study NCT04590742 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: melatonin 6mg
Description: 6 weeks of melatonin (6mg) given to patient
Study NCT04768933 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Toddler Milk
Description: At least three 130 mL servings daily of study formula are recommended for a total daily intake of 390 mL. Study participants will continue this feeding regimen Days 4 to 28 (approximately 4 weeks).
Study NCT02018107 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: N-13 ammonia or F-18 fluorodeoxyglucose
Description: PET tracer
Study NCT02018107 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET scan
Description: PET scan
Study NCT02043730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel and Gemcitabine
Description: Chemotherapy will consist of nab-paclitaxel 125 mg/mq over 30 min and gemcitabine 1000 mg/mq weekly on days 1, 8 and 15 of a 28-day cycle
Study NCT02043730 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: gemcitabine 1000 mg/mq over 30 minutes on days 1, 8 and 15 of a 28-day cycle.
Study NCT02043730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: gemcitabine 1000 mg/mq over 30 minutes on days 1, 8 and 15 of a 28-day cycle.
Study NCT04285437 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: infant massage
Description: Mother will be trained how to massage their babies by International Association of Infant Massage (IAIM) Certified Infant Massage Instructor, and then their babies will be massaged by themselves during the first 2 months after birth.
Study NCT02025452 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Rapid diagnostic
Description: Specimens from rectal mucosa will be obtained using flocked swabs at enrolment. Those in 'rapid diagnostic' groups will have them tested using multiplex PCR the day of enrolment and participants with treatable pathogens will have antimicrobials provided. Those in 'delayed diagnostic' groups will have the swabs batched at tested at the conclusion of the study, being treated as per standard of care.
Study NCT02025452 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rapid diagnostic
Description: Specimens from rectal mucosa will be obtained using flocked swabs at enrolment. Those in 'rapid diagnostic' groups will have them tested using multiplex PCR the day of enrolment and participants with treatable pathogens will have antimicrobials provided. Those in 'delayed diagnostic' groups will have the swabs batched at tested at the conclusion of the study, being treated as per standard of care.
Study NCT03088501 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive voice response system
Description: IVR allows the pregnant women, their family members to interact with a computer system using a telephone.Through IVR, women receive a 2-3 minute call that reminds them of lab test, their next follow-up visit and also provides information on child care attendance, breastfeeding, introduction of solid foods, motor development, and sleep.
Study NCT03088501 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mother and baby affairs workshop
Description: Mother and baby affairs workshop will involve antenatal workshop and counseling for parents. The intervention will involve brief talk by health professionals, quiz activities, role-plays on personal hygiene, nutritional food, institutional delivery, precautions at the time of delivery, caring for the baby, feeding of colostrum, homemade baby food, immunization, and family planning measures.
Study NCT02718820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 75mg/m2; q21
Study NCT02718820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200mg, q21
Study NCT00648986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazorac
Description: All patients were to apply topical tazarotene (Tazorac) twice daily to all affected fingernails for 24 weeks.
Study NCT02025452 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Lactobacillus reuteri suspended in vegetable oil, 5 drops/day (1 x 10e8 CFU) x 2 months
Study NCT04590742 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patient given 6 weeks of placebo tablet
Study NCT00673855 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lubricant Eye Drops FID 112903
Description: Lubricant Eye Drops FID 112903 1 drop each eye 1 time
Study NCT00673855 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Optive Lubricant Eye Drops
Description: Optive Lubricant Eye Drops
Study NCT03325309 — intervention group
Intervention type: OTHER
Intervention: Home-based cycling
Description: A single outpatient supervised session followed by a 3-month home-based cycling program tailored to patients' preferences
Study NCT02072629 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training of VHVs in iCCM
Description: Village Health Volunteers will be trained in Integrated Community Case Management (iCCM) of childhood illness
Study NCT01740336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0941
Description: GDC-0941 will be administered QD orally for 5 consecutive days each week.
Study NCT03790423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injection of 18F-ASIS
Description: Each patient will receive one injection of 18F-ASIS (approximately 200 Mbq)
Study NCT03790423 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PET/CT scan
Description: Following one injection of 18F-ASIS the patients will be PET/CT scanned at 1 hour, 2 hours and 4 hours post-injection
Study NCT01264081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: 500 mg PO (orally) twice a day for 28 days (1 cycle). Up to 27 cycles allowed if response seen.
Study NCT00134784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [123I]B-CIT SPECT imaging
Description: To assess \[123I\]B-CIT SPECT imaging
Study NCT02732197 — intervention group
Intervention type: DRUG
Intervention: Sedation
Description: Parturients who received IV thiopental 2 mg kg-1 and if necessary additional 50 mg immediately after spinal anesthesia until reaching at least Ramsay sedation score of 3 (1: patient anxious, agitated or restless, 6: patient with no response to light glabella tap or loud auditory stimulus.).
Study NCT02732197 — intervention group
Intervention type: DRUG
Intervention: No sedation
Description: Parturients did not receive any type of sedation after spinal anesthesia.
Study NCT00919841 — intervention group
Intervention type: OTHER
Intervention: Ultrasound examination
Description: Sequential three-dimension sonographic examination for the uterine size after vaginal delivery. The examination will be performed once a week, until the completion of 7 weeks after delivery.
Study NCT02025452 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Description: Lactobacillus reuteri suspended in vegetable oil, 5 drops/day (1 x 10e8 CFU) x 2 months
Study NCT02025452 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical in appearance to L. reuteri probiotic (same bottle), but simply vegetable oil. Dose is 5 drops/day x 2 months.
Study NCT01347580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Oral Ticagrelor loading dose (180 mg) followed by matching placebo
Study NCT01347580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo followed by oral Ticagrelor loading dose (180 mg)
Study NCT00333203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Next Generation Ophthalmic Irrigating Solution (NGOIS)
Description: Volume sufficient to irrigate adequately during cataract surgery
Study NCT00333203 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BSS Plus
Description: Volume sufficient to irrigate adequately during cataract surgery
Study NCT02316873 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music training
Description: This program was based on the Kodaly and Orff pedagogy and adapted to focus on rhythm and temporal processing.
Study NCT02316873 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Visual arts
Description: This program emphasized visual-spatial and hand skills as well as creativity.
Study NCT00844168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given orally
Study NCT00844168 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03386253 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active tDCS
Description: two 13 minute tDCS sessions separated by 20 minutes in between
Study NCT03386253 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tDCS
Description: sham tDCS session given for same length of time as active
Study NCT03117088 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Checklist ISBAR3
Description: Checklist ISBAR 3~Use of an online based checklist for handovers with the following items:~Identification Situation Background Assessment Recommendation Read- back Risk~Established Checklist as communication tool
Study NCT03117088 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Checklist VICUR
Description: Checklist Vicur~Use of an online based alternative checklist for handovers with the following items:~Vaccination status Insurance status Contact person Utilisation Rehabilitation Organ donor? Patient decree?~alternative checklist missing communication tool
Study NCT03493815 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transabdominal Ultrasound Guided IUD Insertion
Description: Comparing the utility of ultrasound-guided intrauterine device (IUD) insertion compared to traditional blind insertion
Study NCT03493815 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Blind IUD Insertion
Description: Comparing the utility of ultrasound-guided intrauterine device (IUD) insertion compared to traditional blind insertion
Study NCT02919969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks.
Study NCT01842633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol and Caffeine
Description: Caplets containing 500 milligrams (mg) of paracetamol and 65 mg of caffeine
Study NCT01842633 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Caplets containing 200 mg of ibuprofen
Study NCT01842633 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo caplets
Study NCT00003830 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional surgery
Description: Sentinel node resection immediately followed by axillary dissection.
Study NCT00003830 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sentinel node resection followed by node examination
Description: Sentinel node resection followed by node examination then axillary dissection if positive sentinel node. No axillary dissection for negative sentinel node.
Study NCT03811093 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Care as Usual Group
Description: Each participant randomly assigned to the Care As Usual Group will undergo nine therapy sessions over three weeks using a fully functioning invisa-RED Technology Elite device.
Study NCT03811093 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham Group
Description: Each participant randomly assigned to the Sham Group will undergo nine therapy sessions over three weeks using a non functioning invisa-RED Technology Elite device.
Study NCT00559494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: Minocycline IV BID x 7 days (first 10 patients 200 mg/dose, subsequent patients adjusted based on pharmacodynamic profiling to 800 mg loading dose, tapered 100 mg each dose to 400 mg then maintain at 400mg until day 7)
Study NCT00559494 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Normal saline 250cc via central line similar to minocycline arm administration protocol
Study NCT00559494 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SCPP augmentation
Description: maintenance of spinal cord perfusion pressure at 75 mmHg with fluids and inotrope protocol
Study NCT00559494 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: SCPP control
Description: maintenance of Mean arterial pressure of >65 mmHg with fluids and inotropes protocol without spinal cord perfusion pressure as target or guiding therapy
Study NCT01239862 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autologous cell transplantation
Description: Intrabronchial Instillation Of Bone Marrow Derived Mononuclear Cells
Study NCT00541788 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Administration of Common Sage
Description: Administration of Common Sage
Study NCT03235739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxegol 25 MG
Description: Oral Naloxegol 25 MG
Study NCT03235739 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching oral placebo
Study NCT04533893 — intervention group
Intervention type: OTHER
Intervention: Medical simulator (3B Scientific Lilly Pro) and Platform combining simulator sensor data with OSCE scores
Description: Hands-on training app combining OSCE scoring criteria with sensor data retrieved from the simulator's sensors was used for hands-on performance evaluation.
Study NCT03864575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg
Description: Celecoxib 400 mg/day in combination with nivolumab fixed dose
Study NCT02360761 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: VATS
Description: Patients undergo lobectomy,wedge resection, or anatomical segmentectomy by thoracoscopic surgery or video assisted thoracoscopic surgery.
Study NCT02360761 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: VATS
Description: Patients undergo lobectomy,wedge resection, or anatomical segmentectomy by thoracoscopic surgery or video assisted thoracoscopic surgery.
Study NCT04675112 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Treatment (CBT) and Tinnitus Retraining Therapy (TRT)
Description: CBT is a psychologically informed treatment. Depending on individual patient needs, relevant areas of tinnitus education and management/self-management strategies, such as managing the emotional consequences of tinnitus, rapid relaxation, managing fear and avoidance behaviors and changing unhelpful thoughts and beliefs, are applied in accordance to a published manual \[10\].~TRT is based on the neurophysiological model focusing more on education and sound therapy than on analytical cognitive and behavioral interventions. A TRT program is usually included in a management scheme with hearing aids.
Study NCT04675112 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive Behavioral Treatment (CBT) and Tinnitus Retraining Therapy (TRT)
Description: CBT is a psychologically informed treatment. Depending on individual patient needs, relevant areas of tinnitus education and management/self-management strategies, such as managing the emotional consequences of tinnitus, rapid relaxation, managing fear and avoidance behaviors and changing unhelpful thoughts and beliefs, are applied in accordance to a published manual \[10\].~TRT is based on the neurophysiological model focusing more on education and sound therapy than on analytical cognitive and behavioral interventions. A TRT program is usually included in a management scheme with hearing aids.
Study NCT01818141 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: Vancomycin 125mg by mouth every 6 hours for 10 days
Study NCT01818141 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fidaxomicin
Description: Fidaxomicin 200mg by mouth every 12 hours for 10 days
Study NCT01740336 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to GDC-0941